Madrigal Pharmaceuticals Undervalued by 76.0% According to DCF Analysis

Madrigal Pharmaceuticals' share price has surged 271.3% over 5 years, but recent news flow has focused on its position in pharmaceuticals and biotech. The stock scores 5 out of 6 on our valuation checklist, indicating it is undervalued on most metrics. A discounted cash flow model projects a 76.0% discount to the estimated intrinsic value of $1,805.54 per share, suggesting the shares are significantly undervalued.